Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Nervenblockade des Plexus brachialis im Vergleich zur Standardversorgung zur geschlossenen Reposition von Frakturen des distalen Radius bei Erwachsenen – die BLOCK-Studie. eine nationale multizentrische randomisierte kontrollierte Studie

16. September 2026 aktualisiert von: Nordsjaellands Hospital

The aim of the project is to evaluate the beneficial and harmful effects of an ultrasound-guided brachial plexus nerve block for patients with a distal radius (wrist) fracture in the need of realignment of fractured bone endings without cutting the skin (closed reduction), in comparison to a haematoma block, which is standard care in Denmark.

Every participant will receive one of the following types of anaesthesia for the realignment of the wrist fracture:

  1. A nerve block of the arm (plexus brachialis block)
  2. A haematoma block, which is the current standard anaesthesia in the emergency departments.

Studienübersicht

Studientyp

Interventionell

Einschreibung (Geschätzt)

1716

Phase

  • Phase 4

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Capital Region
      • Hillerød, Capital Region, Dänemark, 3400
        • Copenhagen University Hospital - North Zealand Hillerød

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Adults (age ≥ 18 years) with a distal radius fracture in need of closed reduction

Exclusion Criteria:

  • Patients who would never qualify for surgery according to local guidelines
  • Lack of informed consent
  • No Danish Central Person Register (CPR) number
  • Allergies to the trial medication
  • Distal radius fracture initially deemed to require surgery regardless of the outcome of the closed reduction
  • Open fractures (fracture-related wound requiring sutures)
  • Other fractures on the same extremity ((NOT including distal ulna fracture(s))
  • Bilateral distal radius fractures both requiring closed reduction
  • Concomitant medical or surgical condition taking priority over the closed reduction of the distal radius fracture.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Doppelt

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Intervention group

Ultrasound-guided brachial plexus nerve block. A total of 30 ml of lidocaine (10 mg/ml) with adrenaline (5 ug/ml) will be administered in multiple injections.

The block will be performed as either a lateral infraclavicular brachial plexus block or an axillary brachial plexus block

Aktiver Komparator: Control group

Haematoma block with local anaesthetics i.e. lidocaine with adrenaline

Participants will receive no peripheral nerve block and receive a haematoma block, with or without supplemental sedation and/or systemic analgesia for the closed reduction according to local guidelines and clinical practices

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Zeitfenster
Kumulativer Anteil der Patienten mit distaler Radiusfrakturoperation
Zeitfenster: 90 Tage nach geschlossener Reduktion
90 Tage nach geschlossener Reduktion

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Composite outcome of treatment related complications
Zeitfenster: 90 days after closed reduction

loco-regional neurological complications from affected arm, local anaesthetic systemic toxicity, soft tissue injuries (including skin injuries) related to the closed reduction procedure, infection at the site of needle puncture, vessel puncture requiring subsequent treatment (including compression), pneumothorax, allergic reaction, new bone or joint injury (e.g. dislocation or fracture) after the closed reduction and/or pulmonary embolism

90 days after closed reduction
Patient Rated Wrist Evaluation (PRWE)
Zeitfenster: 90 days after closed reduction

The PRWE is a patient-reported outcome and the PRWE-score is calculated from the Danish-validated translation of the PRWE questionnaire

90 days after closed reduction
Maximum pain score in the affected wrist during closed reduction(s)
Zeitfenster: 0-12 hours after the closed reduction

The pain outcomes are patient-reported as a Numerical Rating Scale (NRS) score on a scale from 0=no pain to 10=worst pain imaginable. If the patient has the closed reduction performed more than one time, the patient will be asked to report the worst pain experienced during all the attempts of a closed reduction.

0-12 hours after the closed reduction
Proportion of patients with unacceptable radiographic fracture position immediately after closed reduction
Zeitfenster: 0 -24 hours after closed reduction

The radiographic fracture position is evaluated according to the American Academy of Orthopaedic Surgerons (AAOS) guidelines. The fracture position is unacceptable if the fracture has a radial shortening > 3 mm, > 10 degrees dorsal tilt of the articular surface of radius from a perpendicular line on the longitudianal axis of radius or intra-articular displacement or step-off > 2 mm.

0 -24 hours after closed reduction

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Anzahl der Versuche für die geschlossene Reduktion
Zeitfenster: Unmittelbar nach geschlossener Reduktion
Unmittelbar nach geschlossener Reduktion
Anteil der einzelnen Komplikationen am zusammengesetzten sekundären Endpunkt
Zeitfenster: 90 Tage nach geschlossener Reduktion
90 Tage nach geschlossener Reduktion
Pain at rest in the affected wrist immediately, 90 days, and 12 months after closed reduction
Zeitfenster: 0-12 hours, 90 days and 12 months after closed reduction

The pain outcomes are patient-reported as a Numerical Rating Scale (NRS) score on a scale from 0=no pain to 10=worst pain imaginable.

0-12 hours, 90 days and 12 months after closed reduction
Maximum pain in the affected wrist within the first 24 hours after closed reduction
Zeitfenster: 24-36 hours after the closed reduction.

The pain outcomes are patient-reported as an NRS score on a scale from 0=no pain to 10=worst pain imaginable.

24-36 hours after the closed reduction.
Proportion of patients with complex regional pain syndrome (CRPS)
Zeitfenster: 90 days and 12 months after closed reduction

CRPS is defined according to the Budapest Criteria

90 days and 12 months after closed reduction
Disabilities of the Arm, Shoulder, and Hand (DASH) score
Zeitfenster: 90 days and 12 months after closed reduction

DASH-score is calculated from the Danish-validated translation of the DASH questionnaire

90 days and 12 months after closed reduction
Patient Rated Wrist Evaluation (PRWE)
Zeitfenster: 12 months after closed reduction

PRWE-score is calculated from the Danish-validated translation of the PRWE questionnaire

12 months after closed reduction
Quality of life (EQ-5D-5L) score
Zeitfenster: 90 days and 12 months after closed reduction

The Danish translation of the EQ-5D-5L questionnaire is used and the EQ-5D-5L-score is calculated based on the Danish EQ-5D-5L value set

90 days and 12 months after closed reduction
Difficulty of closed reduction of the fracture
Zeitfenster: Immediately after closed reduction

The doctor reported ease on a numeric rating scale from 0-10; 0=very easy, 10=very difficult)

Immediately after closed reduction
Discomfort related to the anaesthetic procedure
Zeitfenster: 0-12 hours after closed reduction

The discomfort is a patient-reported outcome on a numeric rating scale from 0-10; 0=no discomfort, 10=very uncomfortable

0-12 hours after closed reduction
Overall satisfaction with the treatment 0 to 24 hours after initiation of the anaesthesia
Zeitfenster: 24 hours after closed reduction

The overall satisfaction is a patient-reported outcome on a numeric rating scale from 0-10; 0=very unsatisfied, 10=very satisfied. When evaluating the treatment, the patient is specifically asked to include all elements of the treatment including: the anaesthetic (procedure and following effects), the experience during the closed reduction and the pain and general sensation in the arm/wrist in the first 24 hours after the treatment commencement.

24 hours after closed reduction
Proportion of patients with unacceptable radiographic position at first follow-up in the orthopaedic out-patient clinic (typically 10-14 days post-reduction)
Zeitfenster: 10-14 days after closed reduction

The radiographic fracture position is evaluated according to the American Academy of Orthopaedic Surgerons (AAOS) guidelines. The fracture position is unacceptable if the fracture has a radial shortening > 3 mm, > 10 degrees dorsal tilt of the articular surface of radius from a perpendicular line on the longitudianal axis of radius or intra-articular displacement or step-off > 2 mm.

10-14 days after closed reduction
Proportion of patients having one or more serious adverse events (SAEs), including events related to loss of hand function
Zeitfenster: Within 90 days after closed reduction

A SAE is defined as an adverse event that leads to the following incidents:

  • Death
  • Life threatening injury or disease
  • Severe or permanent disability
  • Admission to the hospital or prolongation of hospitalisation

Surgical reduction of the distal radius fracture, including relevant admission to hospital, will not be catagorised as a SAE.

Within 90 days after closed reduction
Proportion of patients having one or more adverse events (AEs)
Zeitfenster: Within 24 hours after closed reduction

An AE is defined as any harmful and unintended event, sign, or symptom, that appear during the trial period, regardless of whether this AE is considered related to the treatment or not.

Within 24 hours after closed reduction

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Cecilie D Harwood, MD, PhD-fellow, Copenhagen University Hospital - North Zealand
  • Hauptermittler: Anne-Sofie Jellestad, MD, PhD-fellow, Copenhagen University Hospital - North Zealand

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

10. Dezember 2024

Primärer Abschluss (Geschätzt)

24. November 2026

Studienabschluss (Geschätzt)

24. August 2027

Studienanmeldedaten

Zuerst eingereicht

6. November 2024

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

6. November 2024

Zuerst gepostet (Tatsächlich)

7. November 2024

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

21. September 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

16. September 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren